# A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)

> **NCT05624281** · — · NO_LONGER_AVAILABLE · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Lung Diseases, Interstitial (in Pediatric Populations)
- Childhood Interstitial Lung Disease (chILD)

## Interventions

- **DRUG:** nintedanib

## Key facts

- **NCT ID:** NCT05624281
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624281, "A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05624281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*